Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
| Last: | $14.227 |
|---|---|
| Change Percent: | 1.44% |
| Open: | $14.24 |
| Close: | $14.0255 |
| High: | $14.5 |
| Low: | $14.03 |
| Volume: | 324,174 |
| Last Trade Date Time: | 03/09/2026 12:45:51 pm |
| Market Cap: | $1,932,123,392 |
|---|---|
| Float: | 126,527,384 |
| Insiders Ownership: | 2.24% |
| Institutions: | 102 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.auriniapharma.com |
| Country: | CA |
| City: | Edmonton |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Aurinia Pharmaceuticals Inc (NASDAQ: AUPH).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
